Statins: adherence and side-effects

References

• Mitka M. Improving medication adherence promises great payback, but poses tough challenge. JAMA. 2010; 303(9): 825.
   PubMed Web of Science ®Google Scholar
• Shroufi A, Powles JW. Adherence and chemoprevention in major cardiovascular disease: a simulation study of the benefits of additional use of statins. J Epidemiol Community Health. 2010; 64(2): 109–113.
   PubMed Web of Science ®Google Scholar
• Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002; 288(4): 455–461.
   PubMed Web of Science ®Google Scholar
• Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998; 279(18): 1458–1462.
   PubMed Web of Science ®Google Scholar
• Dragomir A, Cote R, White M, et al. Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting. Value Health. 2010; 13(1): 87–94.
   PubMed Web of Science ®Google Scholar
• Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008; 155(4): 772–779.
   PubMed Web of Science ®Google Scholar
• McGinnis BD, Olson KL, Delate TM, Stolcpart RS. Statin adherence and mortality in patients enrolled in a secondary prevention program. Am J Manag Care. 2009; 15(10): 689–695.
   PubMed Web of Science ®Google Scholar
• Wei L, Fahey T, MacDonald TM. Adherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour vs. drug effects and 10-year follow-up of outcome. Br J Clin Pharmacol. 2008; 66(1):110–116.
   PubMed Web of Science ®Google Scholar
• Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol. 2007; 166(3): 348–354.
   PubMed Web of Science ®Google Scholar
• Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation. 2009; 119(15): 2051–2057.
   PubMed Web of Science ®Google Scholar
• Mann DM, Woodward M, Muntner P, et al. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010; 44(9): 1410–1421.
   PubMed Web of Science ®Google Scholar
• Bertakis KD, Azari R, Helms LJ, et al. Gender differences in the utilization of health care services. J Fam Pract. 2000; 49(2): 147–152.
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353(5): 487–497.
   PubMed Web of Science ®Google Scholar
• Yang CC, Jick SS, Testa MA. Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics. Br J Clin Pharmacol. 2003; 56(1): 84–91.
   PubMed Web of Science ®Google Scholar
• Mann DM, Ponieman D, Leventhal H, Halm EA. Predictors of adherence to diabetes medications: the role of disease and medication beliefs. J Behav Med. 2009; 32(3): 278–284.
   PubMed Web of Science ®Google Scholar
• Vicki F, Sinclair F, Wang H, et al. Patients' perspectives on nonadherence to statin therapy: a focus-group study. Perm J. 2010; 14(1): 4–10.
   Google Scholar
• Roshan F, Saeed M, Agewall S. Patients' self-estimated likelihood of taking a statin as prescribed after different types of prognostic information. Atherosclerosis. 2010; 212(2): 586–588.
   PubMed Web of Science ®Google Scholar
• Helin-Salmivaara A, Lavikainen PT, Korhonen MJ, et al. Pattern of statin use among 10 cohorts of new users from 1995 to 2004: a register-based nationwide study. Am J Manag Care. 2010; 16(2): 116–122.
   PubMed Web of Science ®Google Scholar
• Choudhry NK, Setoguchi S, Levin R, et al. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. Pharmacoepidemiol Drug Saf. 2008; 17(12): 1189–1196.
   PubMed Web of Science ®Google Scholar
• Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. [Cochrane Review]. In the Cochrane Library, Issue 3, 2010. Oxford: Update Software.
   Google Scholar
• Schedlbauer A, Schroeder K, Fahey T. How can adherence to lipid-lowering medication be improved? A systematic review of randomized controlled trials. Fam Pract. 2007; 24(4): 380–387.
   PubMed Web of Science ®Google Scholar
• McHorney CA. The Adherence Estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. Curr Med Res Opin. 2009; 25(1): 215–238.
   PubMed Web of Science ®Google Scholar
• Beltowski J. Statins and ALS: the possible role of impaired LXR signaling. Med Sci Monit. 2010; 16(3): RA73-RA78.
   Web of Science ®Google Scholar
• Sorensen HT, Riis AH, Lash TL, Pedersen L. Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes. 2010; 3(4): 413–417.
   PubMed Web of Science ®Google Scholar
• Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008; 8(6): 373–418.
   PubMed Web of Science ®Google Scholar
• Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation. 2002; 106(8): 1024–1028.
   PubMed Web of Science ®Google Scholar
• Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006; 114(25): 2788–2797.
   PubMed Web of Science ®Google Scholar
• Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007; 29(8): 1761–1770.
   PubMed Web of Science ®Google Scholar
• Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther. 2005; 19(6): 403–414.
   PubMed Web of Science ®Google Scholar
• Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009; 150(12): 858–868.
   PubMed Web of Science ®Google Scholar
• Echaniz-Laguna A, Mohr M, Tranchant C. Neuromuscular symptoms and elevated creatine kinase after statin withdrawal. N Engl J Med. 2010; 362(6): 564–565.
   PubMed Web of Science ®Google Scholar
• Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med. 2008; 359(8): 789–799.
   PubMed Web of Science ®Google Scholar
• McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006; 97(8A): 89C–94C.
   PubMed Web of Science ®Google Scholar
• Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002; 40(3): 567–572.
   PubMed Web of Science ®Google Scholar
• Echaniz-Laguna A, Mohr M, Tranchant C. Neuromuscular symptoms and elevated creatine kinase after statin withdrawal. N Engl J Med. 2010; 362(6): 564–565.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493): 1267–1278.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670–1681.
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Aregawi D, Agloria M, et al. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Clin Ther. 2006; 28(6): 933–942.
   PubMed Web of Science ®Google Scholar
• Stein EA, Ballantyne CM, Windler E, et al. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol. 2008; 101(4): 490–496.
   PubMed Web of Science ®Google Scholar
• Backes JM, Moriarty PM, Ruisinger JF, Gibson CA. Effects of once weekly rosuvastatin among patients with a prior statin intolerance. Am J Cardiol. 2007; 100(3): 554–555.
   PubMed Web of Science ®Google Scholar
• Ruisinger JF, Backes JM, Gibson CA, Moriarty PM. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol. 2009; 103(3): 393–394.
   PubMed Web of Science ®Google Scholar
• Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J. 2002; 144(4): 674–647.
   PubMed Web of Science ®Google Scholar
• Backes JM, Venero CV, Gibson CA, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother. 2008; 42(3): 341–346.
   PubMed Web of Science ®Google Scholar
• Rivers SM, Kane MP, Busch RS, et al. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract. 2007; 13(1): 11–16.
   PubMedGoogle Scholar
• Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin. 2007; 23(9): 2183–292.
   PubMed Web of Science ®Google Scholar
• Ezetimibe: an update. Drug Ther Bull. 2009; 47(8): 91–95.
   PubMedGoogle Scholar
• Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003; 24(8): 729–741.
   PubMed Web of Science ®Google Scholar
• Marcoff L, Thompson PD. The role of coenzyme Q10 in statin- associated myopathy: a systematic review. J Am Coll Cardiol. 2007; 49(23): 2231–2237.
   PubMed Web of Science ®Google Scholar
• Schaars CF, Stalenhoef AF. Effects of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr Opin Lipidol. 2008; 19(6): 553–557.
   PubMed Web of Science ®Google Scholar
• Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. 1993; 33(3): 226–229.
   PubMed Web of Science ®Google Scholar
• Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007; 99(10): 1409–1412.
   PubMed Web of Science ®Google Scholar
• Young JM, Florkowski CM, Molyneux SL, et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol. 2007; 100(9): 1400–1403.
   PubMed Web of Science ®Google Scholar
• Mabuchi H, Nohara A, Kobayashi J, et al. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis. 2007; 195(2): e182–189.
   PubMed Web of Science ®Google Scholar
• Heber D, Yip I, Ashley JM, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr. 1999; 69(2): 231–236.
   PubMed Web of Science ®Google Scholar
• Huang CF, Li TC, Lin CC, et al. Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients. Eur J Cardiovasc Prev Rehabil. 2007; 14(3): 438–440.
   PubMed Web of Science ®Google Scholar
• Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008; 101(12): 1689–1693.
   PubMed Web of Science ®Google Scholar
• Becker DJ, Gordon RY, Halbert SC, et al. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009; 150(12): 830–839.
   PubMed Web of Science ®Google Scholar
• Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol. 2010; 105(2): 198–204.
   PubMed Web of Science ®Google Scholar
• Venero CV, Venero JV, Wortham DC, Thompson PD. Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol. 2010; 105(5): 664–646.
   PubMed Web of Science ®Google Scholar
• Prasad GV, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation. 2002; 74(8): 1200–1201.
   PubMed Web of Science ®Google Scholar
• Lapi F, Gallo E, Bernasconi S, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. Br J Clin Pharmacol. 2008; 66(4): 572–574.
   PubMed Web of Science ®Google Scholar
• Roselle H, Ekatan A, Tzeng J, et al. Symptomatic hepatitis associated with the use of herbal red yeast rice. Ann Intern Med. 2008; 149(7): 516–517.
   PubMed Web of Science ®Google Scholar
• Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med. 2010; 170(19): 1722–1727.
   PubMed Web of Science ®Google Scholar
• Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol. 2010; 105(5): 978–980.
   PubMed Web of Science ®Google Scholar
• Rzouq FS, Volk ML, Hatoum HH, et al. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am J Med Sci. 2010; 340(2): 89–93.
   PubMed Web of Science ®Google Scholar
• Tolman KG. The liver and lovastatin. Am J Cardiol. 2002; 89(12): 1374–1380.
   PubMed Web of Science ®Google Scholar
• De Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy. 2004; 24(5): 584–591.
   PubMed Web of Science ®Google Scholar
• Tolman KG. Defining patient risks from expanded preventive therapies. Am J Cardiol. 2000; 85(12A): 15E–19E.
   PubMed Web of Science ®Google Scholar
• Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis. 2009; 29(4): 412–422.
   PubMed Web of Science ®Google Scholar
• Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol. 2006; 97(8A): 77C–81C.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010; 376(9756): 1916–1922.
   PubMed Web of Science ®Google Scholar
• Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007; 46(5): 1453–1463.
   PubMed Web of Science ®Google Scholar
• Anfossi G, Massucco P, Bonomo K, Trovati M. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutr Metab Cardiovasc Dis. 2004; 14(4): 215–224.
   PubMed Web of Science ®Google Scholar
• Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc. 2010; 85(4): 349–356.
   PubMed Web of Science ®Google Scholar
• Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult reatment panel III). JAMA. 2001; 285(19): 2486–2497.
   PubMed Web of Science ®Google Scholar
• Armitage J. The safety of statins in clinical practice. Lancet. 2007; 370(9601): 1781–1790.
   PubMed Web of Science ®Google Scholar